Gubra A/S (GUBRF) Q3 2026 Sales/Trading Call Transcript
Gubra A/S (GUBRF) Q3 2026 Sales/Trading Call November 6, 2026 4:00 AM EST
Company Participants
Adam Lange – Head of Investor Relations
Markus Rohrwild – Chief Executive Officer
Louise Dalboge – Chief Science Officer
Thomas Langenickel – Chief Medical and Development Officer
Trine Hamann – Head of Gubra CRO
Kristian Borbos – Chief Financial Officer
Conference Call Participants
Romy O’Connor – Van Lanschot Kempen NV
Thomas Bowers – SEB, Research Division
Theodora Beadle – Goldman Sachs Group, Inc., Research Division
Presentation
Operator
Welcome to the conference call. [Operator Instructions].
Now I will hand the conference over to the speakers. Please go ahead.
Adam Lange
Head of Investor Relations
Good morning, everyone, and welcome to Gubra’s conference call covering the Third Quarter of 2026. My name is Adam Lange, Head of Investor Relations at Gubra. And joining me today are members of Gubra’s leadership team, who will walk you through the key developments during the quarter and discuss our financial performance. We’ll do a presentation expected to last approximately 20 to 25 minutes, and we’ll then afterwards open the call for questions. Now on Slide 2, I just need to remind everyone that today, during the presentation and the subsequent Q&A session, we may make forward-looking statements that are subject to risks and uncertainties.
And with that, I will hand over the call to our CEO, Markus Rohrwild, for opening remarks.
Markus Rohrwild
Chief Executive Officer
Good morning. Welcome from my side. Q3 has been very strong for Gubra. We have significant advancements in our R&D pipeline, and we have also seen strong CRO performance. On the biotech side, our 2 partner obesity programs advanced to Phase II, a great achievement for Gubra. And also, we are excited to see our GUB-UCN2, Urocortin-2 analog entering Phase I clinical development. Overall, the CRO has shown 6% growth year-on-year, and our EBIT margin has significantly improved to 25%, which is great.
